LOS ANGELES--(BUSINESS WIRE)--Xcorporeal, Inc. (AMEX:XCR) announced today that The Lancet, a leading medical journal, has published an article on the Company’s Wearable Artificial Kidney (WAK) prototype device in its Journal dated December 15, 2007. The data, from a pilot study conducted by Drs. Andrew Davenport and Victor Gura at the Royal Free and University College Hospital Medical School, London, UK, showed that the WAK’s clearance rate, if sustained and used continuously, could be more effective than conventional three times weekly or daily hemodialysis treatment. This proof of concept study also provides preliminary indications on the safety features of the WAK and permitted the patient to be ambulatory during treatment.
